177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress

Background

In cancer, tumor-secreted factors and surgical stress responses induce the migration of myeloid-derived suppressor cells (MDSC) from the bone marrow to the circulation and tumor microenvironment (TME). Due to severe immunosuppression, this process promotes disease progression and negatively affects treatment outcomes. Limited knowledge exists regarding MDSC in colorectal cancer (CRC). Through the use of flow cytometry and a precise gating strategy, we have identified and quantified 3 classes of MDSC in CRC and confirmed their immunosuppressive capacity. Initial findings show an increase of MDSC. Future investigations will focus on comparing MDSC levels among different CRC stages and examining their spatial distribution in the TME. This research aims to enhance our understanding of how MDSC contribute to tumor cell immune evasion and impact treatment outcomes. End of study: end of 2025.

Trial Design

A cohort of 250 patients with operable CRC have pre- and postoperative blood samples drawn for analysis. Flow cytometry is performed on isolated peripheral blood mononuclear cells. Controls are healthy individuals and patients undergoing surgery for non-malignant disease.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Center for Surgical Science, Zealand University Hospital.

Funding

Familien Erichsen’s Mindefond (The Erichsen Family Memorial Fund).

Disclosure

All authors have declared no conflicts of interest.